Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market

 

MONTREAL, Canada, March 14, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc.
(NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical
company focused on the research, development and commercialization of oncology and antiviral
drugs, today closed its previously announced private placement pursuant to a securities purchase
agreement entered into on March 10, 2022 with certain institutional and accredited investors.

In connection with the private placement, the Company issued (i) 2,301,353 shares of its Common
Stock together with investor warrants (“Investor Warrants”) to purchase up to 2,301,353 shares of
Common Stock, and (ii) 1,302,251 pre-funded warrants (“Pre-Funded Warrants”) with each PreFunded Warrant exercisable for one share of Common Stock, together with Investor Warrants to
purchase up to 1,302,251 shares of Common Stock. Each share of Common Stock and accompanying
Investor Warrant were sold together at a combined offering price of $2.22, and each Pre-Funded
Warrant and accompanying Investor Warrant were sold together at a combined offering price of
$2.219, priced at-the-market under Nasdaq rules.

The Pre-Funded Warrants are immediately exercisable, at a nominal exercise price of $0.001, and may
be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Investor
Warrants have an exercise price of $2.22 per share (subject to adjustment as set forth in the warrant),
are exercisable upon issuance and will expire five years from the date of issuance.
The Company received gross proceeds of approximately $8 million before deducting transaction
related expenses payable by the Company.


Aegis Capital Corp. acted as the Exclusive Placement Agent in connection with the offering.
Additional details regarding the offering will be available in a Form 8-K to be filed by the Company
with the U.S. Securities and Exchange Commission (the “SEC”).


The shares of common stock and warrants described above have not been registered under the
Securities Act of 1933, as amended, and may not be offered or sold in the United States absent
registration with the Securities and Exchange Commission (SEC) or an applicable exemption from
such registration requirements. The securities were offered only to accredited investors. Pursuant to a
registration rights agreement with the investors, the Company has agreed to file one or more
registration statements with the SEC covering the resale of the shares of common stock and the shares
issuable upon exercise of the warrants.


This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation
or sale would be unlawful prior to registration or qualification under the securities laws of any such
state or other jurisdiction.


About Sunshine Biopharma
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the
ongoing COVID-19 pandemic that has claimed the lives of over 6 million people worldwide since it
first appeared in December 2019. Sunshine Biopharma is working on the development of a treatment
for COVID-19 and has completed the synthesis of four potential inhibitors of PLpro and
subsequently identified a lead compound, SBFM-PL4. The Company is currently advancing the
development of SBFM-PL4 in collaboration with the University of Georgia, College of Pharmacy. In
addition, the Company recently signed a collaboration with the University of Arizona aimed at
assessing the efficacy of three University of Arizona PLpro inhibitors in mice.
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have
demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including
Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells.
Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s
Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and
intellectual property pertaining to Adva-27a.


Cautionary Note Regarding Forward Looking Statements
This press release and statements of the Company’s management made in connection therewith
contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future
events. Words such as “may”, “could”, “expects”, “projects,” “intends”, “plans”, “believes”, “predicts”,
“anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended
to identify forward-looking statements. These statements involve known and unknown risks and are
based upon several assumptions and estimates, which are inherently subject to significant uncertainties
and contingencies, many of which are beyond the Company’s control. Actual results may differ
materially from those expressed or implied by such forward-looking statements. Factors that could
cause actual results to differ materially include, but are not limited to, the risk factors described in the
Company’s filings with the SEC. The Company’s SEC filings can be obtained free of charge on the
SEC’s website at www.sec.gov. Except to the extent required by law, the Company expressly disclaims
any obligations or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company’s expectations with respect thereto
or any change in events, conditions, or circumstances on which any statement is based.


For Additional Information:
Sunshine Biopharma Media Contacts:
TraDigital IR
Direct Line: 917-633-8980
[email protected]


Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

Sunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-Market

 

 MONTREAL, Canada, March 10, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc.
(NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical
company focused on the research, development and commercialization of oncology and antiviral
drugs, today announced that it entered into a securities purchase agreement with certain institutional
and accredited investors for aggregate gross proceeds of approximately $8.0 million, before deducting
fees to the placement agent and other offering expenses payable by the Company.


In connection with the offering, the Company will issue 3,603,604 units at a purchase price of $2.22
per unit, priced at-the-market under Nasdaq rules. Each unit consists of 1 share of common stock or
common stock equivalent, and 1 non-tradable warrant, to purchase 1 share of common stock (for a
total of 3,603,604 shares underlying the warrants). No actual units will be issued in the offering.
The warrants each have an exercise price of $2.22, subject to adjustments therein. The warrant has a
term equal to five years from the issuance date.
The offering is expected to close on or about March 14, 2022, subject to the satisfaction of customary
closing conditions.


Aegis Capital Corp. is acting as the Exclusive Placement Agent in connection with the
offering.
Additional details regarding the offering will be available in a Form 8-K to be filed by the Company
with the U.S. Securities and Exchange Commission (the “SEC”).
The shares of common stock and warrants described above have not been registered under the
Securities Act of 1933, as amended, and may not be offered or sold in the United States absent
registration with the Securities and Exchange Commission (SEC) or an applicable exemption from
such registration requirements. The securities were offered only to accredited investors. Pursuant to a
registration rights agreement with the investors, the Company has agreed to file one or more
registration statements with the SEC covering the resale of the shares of common stock and the shares
issuable upon exercise of the warrants.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.


About Sunshine Biopharma
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the
ongoing COVID-19 pandemic that has claimed the lives of over 6 million people worldwide since it
first appeared in December 2019. Sunshine Biopharma is working on the development of a treatment
for COVID-19 and has completed the synthesis of four potential inhibitors of PLpro and
subsequently identified a lead compound, SBFM-PL4. The Company is currently advancing the

development of SBFM-PL4 in collaboration with the University of Georgia, College of Pharmacy. In
addition, the Company recently signed a collaboration with the University of Arizona aimed at
assessing the efficacy of three University of Arizona PLpro inhibitors in mice.
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have
demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including
Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells.
Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s
Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and
intellectual property pertaining to Adva-27a.
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have
demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including
Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells.
Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s
Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and
intellectual property pertaining to Adva-27a.


Cautionary Note Regarding Forward Looking Statements
This press release and statements of the Company’s management made in connection therewith
contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future
events, particularly with respect to the offering described herein. Words such as “may”, “could”,
“expects”, “projects,” “intends”, “plans”, “believes”, “predicts”, “anticipates”, “hopes”, “estimates”
and variations of such words and similar expressions are intended to identify forward-looking
statements. These statements involve known and unknown risks and are based upon several
assumptions and estimates, which are inherently subject to significant uncertainties and contingencies,
many of which are beyond the Company’s control. Actual results (including the anticipated benefits
of the offering described herein) may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause actual results to differ materially include, but are
not limited to, the risk factors described in the Company’s filings with the SEC. The Company’s SEC
filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent
required by law, the Company expressly disclaims any obligations or undertaking to release publicly
any updates or revisions to any forward-looking statements contained herein to reflect any change in
the Company’s expectations with respect thereto or any change in events, conditions, or circumstances
on which any statement is based.

Related Tag: Pharmaceutical Development Company 


For Additional Information:
Sunshine Biopharma Media Contacts:

TraDigital IR
Direct Line: 917-633-8980
[email protected]


Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

SUNSHINE BIOPHARMA EXPANDS ANTI-CORONAVIRUS DRUG DEVELOPMENT PROGRAM BY SIGNING A COLLABORATION AGREEMENT WITH THE UNIVERSITY OF ARIZONA

For Immediate Release February 25, 2022

Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM” and
SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the
research, development and commercialization of oncology and antiviral drugs today announced
that it has entered into an agreement with the University of Arizona for the purposes of advancing
the development of novel PLpro inhibitors discovered by the University of Arizona and the University of
Illinois Chicago researchers. The development of the Company’s lead PLpro inhibitor, SBFMPL4,
is currently continuing at the University of Georgia. At the University of Arizona, the research
effort will focus on determining the in vivo safety, pharmacokinetics, and dose selection properties
of 3 universities owned PLpro inhibitors followed by efficacy testing in MA10 mice infected with
SARS-CoV-2. Molecules showing efficacy in infected mice will be advanced to human trials.


“We are delighted to be working with the University of Arizona Coronavirus research team led by
Dr. Gregory Thatcher as well as the commercialization team at Tech Launch Arizona,” said Dr.
Steve Slilaty, CEO of Sunshine Biopharma. “It is of paramount importance to find a wide array of
inhibitors for PLpro, as this virus encoded protease is responsible for the suppression of the human
immune system, thereby enabling the virus to cause severe illness,” he added.


About the University of Arizona
The University of Arizona, a land-grant university with two independently accredited medical
schools, is one of the nation’s top 50 public universities, according to U.S. News & World Report.
Established in 1885, the university is widely recognized as a student-centric university and has
been designated as a Hispanic Serving Institution by the U.S. Department of Education. The
university ranked in the top 20 in 2019 in research expenditures among all public universities,
according to the National Science Foundation, and is a leading Research 1 institution with $734
million in annual research expenditures. The university advances the frontiers of interdisciplinary
scholarship and entrepreneurial partnerships as a member of the Association of American
Universities, the 66 leading public and private research universities in the U.S. It benefits the state
with an estimated economic impact of $4.1 billion annually.


About Tech Launch Arizona
Tech Launch Arizona is the office of the University of Arizona that creates social and economic
impact through commercializing inventions stemming from university research. The office builds
connections between talented UA faculty, researchers and staff and experienced entrepreneurs
and investors, to create an ecosystem that refines ideas that start in research and innovation
and grows them into products and businesses that benefit society. TLA supports entrepreneurship
through a variety of initiatives, including training startup teams in customer discovery, providing
funding to advance early-stage inventions toward market readiness, and hosting challenges to
help students and faculty move innovative ideas from concept to societal impact. In FY2021, TLA
took in 274 invention disclosures, had 100 U.S. patents issued, and executed 124 licenses and
options for UArizona technologies. The university has launched more than 100 startups since the
office was founded in 2012.


About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date
have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells,
including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine
Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at
McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner
of all patents and intellectual property pertaining to Adva-27a.


Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements that are based on current expectations, forecasts, and
assumptions of Sunshine Biopharma, Inc. (the “Company”) that involve risks as well as uncertainties that could cause
actual outcomes and results to differ materially from those anticipated or expected. These statements appear in a
number of places in this release and include all statements that are not statements of historical fact regarding the
intent, belief or current expectations of the Company, including statements related to the Company’s drug
development activities, financial performance, and future growth. These risks and uncertainties are further described
in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and
the timing of certain events could differ materially from those projected in or contemplated by the forward-looking
statements due to a number of factors detailed from time to time in the Company’s filings with the SEC. Reference is
hereby made to cautionary statements and risk factors set forth in the Company’s most recent SEC filings.

Related Tag: Pharma Companies in Canada


For Additional Information:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

Sunshine Biopharma Announces $1,361,000 in Debt Reduction

For Immediate Release
December 22, 2021

 Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a
pharmaceutical company focused on the research, development and commercialization of oncology and antiviral
drugs, today announced that on December 20, 2021, the Company issued 2,904,833 shares of Common Stock in favor
of RB Capital Partners, Inc. (“RB Capital”) in connection with the conversion of $1,361,000 in convertible debt at an
average conversion price of $0.47 per share. The total debt remaining on the books of the Company is $1,900,000
convertible at an average price of $0.30 per share with maturity dates in April, July and August 2023.
“This debt conversion strengthens the financial condition of the Company and conserves the cash on hand for our
ongoing research and development activities of our antiviral and anticancer drugs,” said, Camille Sebaaly, CFO of
Sunshine Biopharma. “We thank RB Capital for believing in us and for their continued support,” he added.
About Sunshine Biopharma


Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19
pandemic that has claimed the lives of over 5.3 million people worldwide since it first appeared in December 2019.
There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the
illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently
identified a lead compound, SBFM-PL4. The Company is currently advancing the development of SBFM-PL4 in
collaboration with the University of Georgia, College of Pharmacy.


In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the
development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness
of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung
Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are
planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma
is the owner of all patents and intellectual property pertaining to Adva-27a.


Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations, forecasts, and
assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially
from those anticipated or expected, including statements related to the amount and timing of expected revenues
statements related to our financial performance, expected income, distributions, and future growth for upcoming
quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company
with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ
materially from those projected in or contemplated by the forward-looking statements due to a number of factors
detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain
growth or achieve profitability based upon many factors including but not limited to general stock market conditions.
Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have
incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines
noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long

term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)
based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted
at this time.


For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com


SUNSHINE BIOPHARMA EXPANDS BOARD OF DIRECTORS

For Immediate Release
November 3, 2021

Independent Directors Added as Part of Company’s
Application Process to Uplist to Nasdaq


Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has expanded its board of directors from three to five and has appointed three new, independent directors. The three new directors are: Mr. Andrew Tesley, Esq, Mr. JD Kish, CPA and Dr. Rabi Kiderchah, MD. They bring legal, accounting and medical expertise to the Company. The following are their brief biographies:


Andrew Telsey is an “AV” rated attorney licensed to practice law in the State of Colorado since 1980. Since 1984, Mr. Telsey has been President and sole shareholder of Andrew I. Telsey, P.C., Centennial, Colorado, a law firm emphasizing securities law, business transactions, mergers and acquisitions and general corporate matters for public and privately held development stage and emerging biopharma companies throughout both the US and internationally, including Russia, China, England, Italy, Mexico, Canada, Switzerland, Germany and several other countries. He has been Sunshine’s legal counsel since its inception.


James (JD) Kish has been a licensed Certified Public Accountant and President of KLA PC, Centennial, CO, an accounting firm, since 1982. He has worked with Sunshine since its inception.


Dr, Rabi Kiderchah is a licensed physician in Canada. From 2000 until August 2021, he was working at Argenteuil Hospital, Lachute, Quebec, Canada, as an emergency room physician. He has also worked as what is referred to in Canada as a “medecins depanneurs”, working in rural areas where there are not enough ER doctors. Since August 2011 he has worked at Rabi Kiderchah Medecin Inc. as a freelance physician in the Quebec, Canada area.


“We are delighted to have Andy, JD and Dr. Kiderchah join our team. We welcome them on board and look forward to calling on their expertise in our ongoing efforts to take the Company to new heights,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma.
The Company accepted the resignation of Mr. Camille Sebaaly as a director. Mr. Sebaaly will continue as Chief Financial Officer of the Company.


About Sunshine Biopharma
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 5 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting.
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development of Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner of all patents and intellectual property pertaining to Adva-27a.
Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.


For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com